Skip to main content
Year archive

ACTINOGEN MEDICAL LIMITED — 2023 filings

All 69 regulatory filings released by ACTINOGEN MEDICAL LIMITED (ACW) in 2023, sourced directly from the official regulator.

69 Filings
2023 Period
2023 filings (69)
Filing Released Lang
First site activated in ACW XanaMIA Phase 2b AD trial 3 pages 257.9KB
Capital/Financing Update
2023-12-19 English
Notification of cessation of securities - ACW 4 pages 23.9KB
Regulatory Filings
2023-12-12 English
Application for quotation of securities - ACW 8 pages 34.2KB
Share Issue/Capital Change
2023-11-30 English
Appendix 3Ys x 5 10 pages 382.4KB
Director's Dealing
2023-11-30 English
ACW XanaCIDD trial enrolment exceeds 50 percent 3 pages 236.5KB
Capital/Financing Update
2023-11-27 English
Actinogen receives $4.8 million R&D tax incentive rebate 2 pages 238.1KB
Capital/Financing Update
2023-11-27 English
Notification of cessation of securities - ACW 4 pages 23.9KB
Share Issue/Capital Change
2023-11-27 English
Appendix 3Y-Dr Geoff Brooke 2 pages 220.6KB
Director's Dealing
2023-11-27 English
Appendix 3Y-Dr George Morstyn 2 pages 219.4KB
Director's Dealing
2023-11-27 English
Actinogen 2023 AGM - Chairs address and CEOs presentation 24 pages 2.6MB
AGM Information
2023-11-16 English
Results of AGM 4 pages 246.9KB
Declaration of Voting Results & Voting Rights Announcements
2023-11-16 English
Amended Constitution 56 pages 772.6KB
Governance Information
2023-11-16 English
ACW CEO presents at Bell Potter Healthcare Conference 2023 28 pages 3.4MB
Investor Presentation
2023-11-14 English
Actinogen appoints William Souter as new CFO 3 pages 254.3KB
Board/Management Information
2023-11-07 English
Application for quotation of securities - ACW 7 pages 30.1KB
Share Issue/Capital Change
2023-11-07 English
Amendment to Actinogen 2023 AGM resolutions 6 to 10 3 pages 225.8KB
AGM Information
2023-10-26 English
ACW CMO presents academic poster at CTAD 2023 conference 4 pages 622.9KB
Regulatory Filings
2023-10-24 English
ACW CEO presentation for meetings at BIO Investor Forum USA 29 pages 3.7MB
Investor Presentation
2023-10-17 English
Actinogen September quarterly activity report & Appendix 4C 9 pages 428.2KB
Interim / Quarterly Report Q1 2024
2023-10-15 English
Letter to Shareholders, Notice of AGM & Proxy Form 64 pages 979.7KB
AGM Information
2023-10-12 English
Annual Report to Shareholders 74 pages 4.7MB
Regulatory Filings
2023-10-12 English
Notification of cessation of securities - ACW 4 pages 23.8KB
Transaction in Own Shares
2023-10-10 English
ACW CEO presents to Dementia Trials Australia conference 21 pages 1.8MB
Investor Presentation
2023-10-05 English
ACW presents to the Asian Society Against Dementia congress 12 pages 1.6MB
Investor Presentation
2023-09-28 English
Date of AGM and Closing Date for Director Nominations 1
AGM Information
2023-09-26 English
Notification of buy-back - ACW 5 pages 24.4KB
Transaction in Own Shares
2023-09-26 English
Change in substantial holding 3 pages 167.2KB
Major Shareholding Notification
2023-09-26 English
Actinogen enhances XanaMIA Phase 2b Alzheimers trial 3 pages 235.1KB
Capital/Financing Update
2023-09-25 English
Change in substantial holding 3 pages 167.2KB
Major Shareholding Notification
2023-09-19 English
Application for quotation of securities - ACW 6 pages 27.8KB
Share Issue/Capital Change
2023-09-14 English
Notification regarding unquoted securities - ACW 7 pages 30.9KB
Share Issue/Capital Change
2023-09-14 English
Appendix 3Y-Dr Geoffrey Brooke 2 pages 236.6KB
Director's Dealing
2023-09-11 English
Appendix 3Y-Dr Steven Gourlay 2 pages 219.1KB
Director's Dealing
2023-09-11 English
Appendix 3Y-Dr George Morstyn 2 pages 220.4KB
Director's Dealing
2023-09-11 English
Appendix 3Y-Mr Malcolm McComas 2 pages 221.2KB
Director's Dealing
2023-09-11 English
Application for quotation of securities - ACW 6 pages 27.9KB
Share Issue/Capital Change
2023-09-10 English
Notification regarding unquoted securities - ACW 5 pages 26.5KB
Share Issue/Capital Change
2023-09-10 English
Actinogen closes successful $10 million rights issue offer 3 pages 236.7KB
Capital/Financing Update
2023-09-06 English
Prof Paul Maruff & Dr Dana Hilt webinar & slide deck 21 pages 1.5MB
Investor Presentation
2023-08-30 English
ACW appoints company for rights issue shareholder contact 3 pages 275.8KB
Capital/Financing Update
2023-08-29 English
ACW secures further $0.5m rights issue shortfall commitment 3 pages 242.8KB
Capital/Financing Update
2023-08-29 English
ACW Appendix 4E and 2023 Annual Report 78 pages 5.4MB
Regulatory Filings
2023-08-29 English
Corporate Governance Statement 16 pages 479.7KB
Governance Information
2023-08-29 English
Appendix 4G 13 pages 389.8KB
Regulatory Filings
2023-08-29 English
Actinogen FY2023 results, following the science 4 pages 291.4KB
Annual Report FY 2023
2023-08-29 English
Prof Paul Maruff on neuroscience drug development & Xanamem 3 pages 232.4KB
Regulatory Filings
2023-08-28 English
Letter to Eligible Shareholders - Rights Issue Opens 4 pages 312.7KB
Capital/Financing Update
2023-08-16 English
Letter to Ineligible Shareholders 2 pages 215.5KB
Capital/Financing Update
2023-08-16 English
ACW secures shortfall commitments of $4.56m for rights issue 3 pages 242.2KB
Capital/Financing Update
2023-08-14 English
Entitlement Offer Prospectus 48 pages 1.6MB
Capital/Financing Update
2023-08-07 English
Actinogen announces $10 million rights offer 5 pages 290.9KB
Capital/Financing Update
2023-08-01 English
Proposed issue of securities - ACW 8 pages 37.6KB
Capital/Financing Update
2023-08-01 English
Trading Halt 2 pages 665.7KB
Capital/Financing Update
2023-07-30 English
Quarterly Activity Report & Appendix 4C 8 pages 415.3KB
Interim / Quarterly Report Q4 2023
2023-07-30 English
ACW CEO presents at Bioshares Biotech Summit 27 pages 2.9MB
Investor Presentation
2023-07-24 English
Actinogen CMO presents academic poster to AAIC Conference 3 pages 555.6KB
Regulatory Filings
2023-07-16 English
ACW CEO presentation on emerging oral Alzheimers therapies 21 pages 1.8MB
Investor Presentation
2023-06-20 English
ACW CEO & CMO present at BIO International Convention 25 pages 1.8MB
Investor Presentation
2023-06-04 English
ACW AD trial amendment and Clinical Science Forum slides 36 pages 2.1MB
Investor Presentation
2023-05-23 English
Quarterly Activity Report & Appendix 4C 7 pages 334.5KB
Interim / Quarterly Report Q3 2023
2023-04-23 English
Actinogen CMO presents at ADPD 2023 conference 28 pages 1.4MB
Investor Presentation
2023-03-30 English
Application for quotation of securities - ACW 7 pages 29.5KB
Share Issue/Capital Change
2023-03-19 English
ACW appoints Dr Nicki Vasquez as a Non-Executive Director 3 pages 252.4KB
Board/Management Information
2023-02-28 English
Appendix 3X - Dr Nicki Vasquez 2 pages 157.8KB
Director's Dealing
2023-02-28 English
Actinogen CEO presents to Spark Plus Biotech conference 25 pages 1.7MB
Investor Presentation
2023-02-23 English
Appendix 4D & Half-Year Financial Statements 26 pages 1.4MB
Interim / Quarterly Report H1 2023
2023-02-21 English
Actinogen appoints Dr Dana Hilt as Chief Medical Officer 3 pages 248.0KB
Board/Management Information
2023-01-31 English
Quarterly Activity Report & Appendix 4C 10 pages 397.6KB
Interim / Quarterly Report Q2 2023
2023-01-29 English
ACW CEO presentation Sachs Neuroscience and JPM week 30 pages 1.6MB
Investor Presentation
2023-01-08 English